Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Trial Profile

Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Transcrocetinate sodium (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Diffusion Pharmaceuticals
  • Most Recent Events

    • 08 Feb 2017 According to Diffusion Pharmaceuticals media release, data from this study has been published in the print edition of the peer-reviewed Journal of Neurosurgery.
    • 13 May 2016 Results published in the Journal of Neurosurgery (JNS), according to Diffusion Pharmaceuticals media release.
    • 08 Jan 2016 Status changed from active, no longer recruiting to completed, according to a Diffusion Pharmaceuticals LLC media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top